Stage IV Lung Cancer Patient Still Benefiting from Dendritic Cell Vaccine 15 Years Later

I received this forwarded email today from the nephew of a patient who was in our clinical trial in 1998-1999 using dendritic cells. We had tried to follow up with her but could not locate her due to a move.

The dendritic cell vaccine that was used on her was the subject of the patent cited below.

June 7, 2014

Dear Riordan Clinic Researchers

I am writing to you in regards to research that you did in 1998-1999. I know that in dealing with cancer patients you must encounter many sad stories, so I thought you would like to hear one with a happy ending. I have looked on your web page and I don’t see that you are still doing research on this project but I thought you would be interested in the results anyway…..maybe they will spark a new research project.

My mother passed away a while back and I have been going through her papers. She saved all the information on my aunt’s (her sister) cancer treatment so I can actually give you accurate details below.

In the fall of 1998 my Aunt, XXX XXXXX was diagnosed with non-small cell lung cancer. She lived in Canada at the time but chose to go to the Mayo Clinic in Minnesota for radiation treatment since she felt their machines were better. The Mayo Clinic determined that there was a mass of large cell carcinoma, metastic grade 4 which had grown so large that it had fractured her clavicle. They knew this was not the site of the primary tumor but were not able to identify the primary location. There were multiple small tumors scattered throughout the area.

She chose to have radiation treatments of the tumor below the clavical. She then visited the Garvey Institute in Kansas, for what the papers I have call leukapheresis procedure. I know she collected her urine for a number of days and that somehow parts of it were extracted and perhaps parts of blood samples were used also. From this a fluid using the patient’s own tumor material and dendritic cells was made. I assume the study she was a part of was not FDA approved because she had to go to San Jose, Costa Rica to be injected with the finished extract. When she returned home to Canada she followed an organic juicing diet for a period of time.

That was now 15 years ago. My aunt is now 76 years old and still alive and well with no current sign of cancer. Since this time she and my uncle have built a new home in Canada, sold that home, and have moved to Costa Rica full time. She hikes and enjoys all kinds of outdoor activities. They eat a primarily vegetarian diet, supplemented with chicken and fish. They spent a couple weeks with us in California last summer and this fall we hope to make our first trip to visit them in Costa Rica. I have always been surprised that the Garvey Clinic never did follow up questionnaires (sic) with her to see how she was doing since she was such a success story. She proves that even someone with stage 4 metastatic can should not give up hope and should look for treatments that have the potential to help or cure them.

I am sure that information on her diagnosis and treatment must be in your records, but I do have copies of the material she was given, if anyone wants more information.



United States Patent 7,749,495
Riordan July 6, 2010
Method for inducing an anti-tumor and anti-cachexia immune response in mammals

The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.

Inventors: Riordan; Neil H. (Chandler, AZ)
Assignee: Aidan, Inc. (Tempe, AZ)
Family ID: 26920848
Appl. No.: 12/126,744
Filed: May 23, 2008

As many as 32,000 kids infected with drug-resistant TB: report

Reuters report today on drug-resistant tuberculosis.

It reminds me of a report 5 years ago from Russia by Erokhin et al. They gave intravenous expanded autologous mesenchymal cells to patients with drug-resistant tuberculosis and saw improvement.1

A new publication just came our of Sweden–a phase I safety trial of the same cell population in patients with multi-drug resistant and extremely drug resistant tuberculosis concluded: “MSCs as an adjunct therapy are safe and can now be explored further for the treatment of patients with MDR or XDR tuberculosis in combination with standard drug regimens. Adjunct treatment with MSCs needs to be evaluated in controlled phase 2 trials to assess effects on immune responses and clinical and microbiological outcomes.2

It would be interesting in someone did a trial expanded allogenic umbilical cord-derived mesenchymal stem cells (huMSCs) vs. autologous bone marrow. huMSCs have been shown to be more effective than autologous and allogenic cells in a number of conditions.

1. Probl Tuberk Bolezn Legk. 2008;(10):3-6.
[Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis].

The study undertaken 3 years ago examined the effect of systemic transplantation of autologous mesenchymal stem cells (MSC) in the complex therapy of 27 patients with pulmonary tuberculosis, including 15 patients with multidrug-resistant pulmonary tuberculosis and 12 with extensive drug resistance of Mycobacterium tuberculosis. All the patients were bacteria-discharging persons with disseminated destructive processes in lung tissue, most (n=17) of them had chronic fibrocavernous tuberculosis. In all the patients, previous long specific antituberculous treatment was ineffective or inadequately effective. After systemic MSC transplantation, 16 patients were followed up for 1.5-2 years or more and the remaining 11 patients for at least 6 months. After MSC administration, a positive clinical effect was observed in all 27 cases; bacterial discharge stopped in 20 patients after 3-4 months; resolution of sustained lung tissue cavities further occurred in 11 patients. At present, a persistent remission of a tuberculous process may be stated in 9 of the 16 patients in whom MSCs were transplanted 1.5-2 years, significant positive bacteriological and morphological changes are observed in 6 patients. Thus, inclusion of transplantation of the autologous MSCs propagated in the culture into a course of antituberculous therapy may be a promising procedure for enhancing the efficiency of therapy in patients with resistant forms of pulmonary tuberculosis.

2.Lancet Respir Med. 2014 Feb;2(2):108-22.
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.
Skrahin A1, Ahmed RK2, Ferrara G3, Rane L4, Poiret T5, Isaikina Y6, Skrahina A7, Zumla A8, Maeurer MJ9.

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis

Press release Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board Translational Biosciences, a subsidiary of Medistem Panama has … [Continue reading]